Clinical trials: Myocardial Ischemia
Microvascular Angina
Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
The purpose of this study is to look at the effects of the drug Ranolazine compared to Placebo on symptoms of chest pain or chest tightness (known as angina), exercise endurance and ability, and changes in blood flow to the very…
- Trial name
- MARINA (NCT02147067)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Emory University
Slow Coronary Flow, Normal, or Near Normal Coronary Angiography
Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow coronary flow is an angiographically diagnosed phenomenon defined as delayed opacification of epicardial arteries in the absence of significant arterial narrowing and blockade.
- Conditions
- Slow Coronary Flow, Normal, or Near Normal Coronary Angiography, Stable Angina
- Trial name
- NCT02254252
- Testing
- Nicorandil, Nitroglycerin
- Volunteers
- 54 people
- Sponsor
- Mashhad University of Medical Sciences
Atherosclerosis, Coronary Artery Disease
Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent System for the treatment of subjects in China with a single de novo atherosclerotic coronary artery…
- Trial name
- PTChina (NCT01285999)
- Testing
- PROMUS Element Coronary Stent System, TAXUS Liberté Coronary Stent System
- Where
- 15 sites in China
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Stroke, Myocardial Infarction
Insulin Resistance Intervention After Stroke Trial
The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
- Conditions
- Stroke, Myocardial Infarction, Diabetes
- Trial name
- IRIS (NCT00091949)
- Testing
- pioglitazone
- Where
- 183 sites in United States, Australia and 6 more
- Volunteers
- 3,876 people
- Sponsor
- Yale University
Coronary Artery Disease
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Subjects being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study.
- Trial name
- GadaCAD 2 (NCT01890434)
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 478 people
- Sponsor
- Bayer
Coronary Artery Disease, Acute Myocardial Ischemia
Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia
The aim of the RIMINI-Trial is to examine the effect of Ranolazine on ischemic myocardium in acute myocardial ischemia. A pilot-trial by Venkatamaran et al.
- Trial name
- RIMINI-Pilot (NCT01797484)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
In STEMI patients undergoing PPCI there is a delayed onset of action of oral P2Y12 receptor inhibitors, including prasugrel and ticagrelor.
- Trial name
- CANTIC (NCT03247738)
- Testing
- Cangrelor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Stable Angina
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
- Trial name
- NCT02575833
- Testing
- Erenumab
- Where
- 33 sites in United States, Bulgaria and 8 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Arterial Occlusion, Angina Pectoris
Comparing TR Band to Statseal in Conjunction With TR Band
The primary objectives of this study are to evaluate the performance of StatSeal Advanced used in conjunction with the TR Band (SSA) as compared to the TR Band without SSA (TRB) relative to: the incidence of peri-procedural…
- Conditions
- Arterial Occlusion, Angina Pectoris, Cardiovascular Diseases, Atherosclerosis
- Trial name
- NCT03028025
- Testing
- StatSeal, TR Band
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- VA Long Beach Healthcare System
Myocardial Infarction
STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction
This study aims at evaluating, in a proof of concept approach, the outcome of patients presenting with acute ST-elevation myocardial infarction within 3 hours of symptom onset in either a pre-hospital setting or community…
- Trial name
- NCT00623623
- Testing
- primary PCI, enoxaparin, catheterisation
- Where
- 201 sites in Austria, Belgium and 14 more
- Volunteers
- 1,899 people
- Sponsor
- Boehringer Ingelheim
Chronic Coronary Occlusion, Vascular Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-LTF (NCT01120379)
- Testing
- XIENCE V® EECSS
- Where
- United States
- Volunteers
- 5,034 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Stress CT Perfusion in Patients With Chest Pain
Our hypothesis is that quantitative 3D analysis of cardiac CT images obtained during vasodilator stress can accurately identify patients presenting at the emergency department with acute chest pain due to underlying…
- Trial name
- NCT01969916
- Testing
- Regadenoson
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Chicago
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Coronary Artery Disease, Mitral Valve Regurgitation
Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol
The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards® PERIMOUNT Magna Mitral Valves in patients undergoing mitral valve replacement with or without concomitant procedures…
- Conditions
- Coronary Artery Disease, Mitral Valve Regurgitation, Mitral Valve Incompetence, Heart Failure
- Trial name
- NCT00853632
- Testing
- CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
- Where
- 15 sites in United States, Austria and 2 more
- Volunteers
- 329 people
- Sponsor
- Edwards Lifesciences
Cardiovascular Disease, Coronary Artery Disease
Radial Artery Versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery
VA patients with coronary artery disease and who have agreed to undergo coronary artery bypass graft surgery would be randomized to receive either radial artery or saphenous vein to the study vessel.
- Trial name
- NCT00054847
- Testing
- saphenous vein graft, radial artery graft
- Where
- 11 sites in United States
- Volunteers
- 733 people
- Sponsor
- US Department of Veterans Affairs
ST Elevation Myocardial Infarction
CArdiac Brief INtervention: A Feasibility Study to Promote Engagement With Cardiac Rehabilitation
Background: An ST-elevation myocardial infarction (STEMI) is a specific type of heart attack. In a previous study, patients requested more mental and emotional support after a STEMI.
- Trial name
- CABIN (NCT05848674)
- Testing
- CArdiac Brief INtervention (CABIN), Refined version of CABIN
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Queen's University, Belfast
Diabetes Mellitus, Type 2, Acute Myocardial Infarction
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined…
- Trial name
- IONM (NCT00191282)
- Testing
- Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine
- Where
- 17 sites in Canada, Croatia and 15 more
- Volunteers
- 1,116 people
- Sponsor
- Eli Lilly and Company
Myocardial Infarction
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction
The purpose of this study is to see if a naturally-occurring hormone called erythropoietin changes the action of platelets in the blood.
- Trial name
- NCT00367991
- Testing
- Recombinant human erythropoietin alfa (drug)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Yale University
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Coronary Heart Disease
Family Heart Health Program: Randomized, Controlled Trial
Background: Family members (spouses, siblings, offspring) of patients with coronary heart disease (CHD) may themselves be at increased risk for developing CHD for genetic, biochemical and/or behavioural reasons.
- Trial name
- FHHP-RCT (NCT00552591)
- Testing
- 12-week risk reduction program, managed by a Heart Health Educator
- Where
- Canada
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Ottawa Heart Institute Research Corporation